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For the great majority of patients with schizophrenia, the
disorder shows a marked tendency towards recurrence.
Although some patients experience only one acute epi-
sode and show few enduring deficits, for many, the reality
is of recurrent acute symptoms and persisting deficits in
the cognitive and psycho-social domains.
When selecting antipsychotic agents, clinicians need to
have regard for the long-term nature of the schizophrenic
illness. Whilst acute episodes may often prove relatively
straightforward to treat, the practical difficulties involved
in establishing the patient on a satisfactory longer-term
treatment are more substantial. A major difficulty is that
many patients remain dissatisfied with their treatment; in
turn, this contributes to the high rates of non-compliance
and of relapse.
Although the new generation, or atypical, antipsychotics
have now been commercially available for almost a dec-
ade, it is unfortunate that the great majority of data con-
cerns only the short-term treatment of the acute disorder.
The extent to which data from short-term, RCTs can be
generalised to everyday clinical practice has been ques-
tioned. Whilst, with the exception of clozapine, these
studies tend to indicate that, in this context, the newer
antipsychotic agents are of similar efficacy in the treat-
ment of acute psychosis, theses studies indicate, nonethe-
less, that there may be considerable differences between
agents, in terms of side effect profile. In particular, there is
evidence of clinically-important differences between
agents in domains such as the liability to induce EPS,
hyperprolactinaemia or weight gain.
There have now been a number of studies in which the
effectiveness of the newer antipsychotics has been investi-
gated, for periods of six months or more. Some of these
studies have adopted a naturalistic design, in order to bet-
ter provide an insight into effectiveness in the 'real- world'
setting. Nonetheless, all such studies have limitations, the
implications of which need to be understood by the prac-
tising clinician.
A major difficulty with many of the longer term studies of
antipsychotics in schizophrenia has been the substantial
drop-out from treatment, which has been observed with
all antipsychotic agents. In part, of course, this illustrates
the practical difficulties many patients experience, in find-
ing a treatment that suits them. The high drop-out rate
makes it difficult to reliably estimate relative efficacy from
these studies. Despite these limitations, however, the
newer studies provide further clear guidance on the likely
side effect profiles of the newer antipsychotics.
Although traditionally not an area of great interest to
researchers, there are now studies examining the ways in
which the new antipsychotics are perceived by the
patients themselves. When guiding patients in the choice
of treatments for schizophrenia, clinicians need to take
full advantage of all of these forms of data.
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